BR9006-1

BR9006-1 is an investigational drug studied in clinical trials for its pharmacokinetics, safety, and tolerability, both alone and in combination with another investigational product, BR9006-2. The available clinical trial data indicate that the study involved healthy male volunteers and was designed to evaluate potential drug-drug interactions between BR9006-1 and BR9006-2. The exclusion criteria for the trial mention hypersensitivity to tamsulosin or mirabegron as well as other ingredients of the investigational products, suggesting that either tamsulosin or mirabegron may be related to or contained within these investigational drugs. However, there is no direct evidence confirming the exact identity or mechanism of action of BR9006-1 from publicly available sources[5][4][2]. No information on its molecular class, target(s), developer(s), or specific indication has been disclosed.